CTI BioPharma (CTIC) Plunges 24%

CTI BioPharma Corp. (CTIC) shares are trading lower by over 24% to $1.97 in midday trading after the company recorded Q4 EPS of ($0.27) vs ($0.22) consensus on revenues of $17.8 million, and reported additional data from the phase III study of its myelofibrosis drug pacritinib into its 10-K filed Thursday night. Approximately 23 million […] View the full post at: CTI BioPharma (CTIC) Plunges 24% Related posts: American Southern Bank Goes Bust Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock Micron Technology to Eliminate 15% of its Workforce